Incretin-based therapies for the treatment of obesity-related diseases
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index; 37 of the 117 sources its claims cite were checked for support.
Abstract
Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and metabolic diseases (i.e. type 2 diabetes [T2D], metabolic dysfunction-associated steatotic liver disease [MASLD]). Lifestyle interventions represent the foundation of obesity treatment, yet an escalation to pharmacological and/or surgical interventions is often needed. Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development. Incretin-based therapies have been associated with a body weight (BW) reduction of ≥5% in at least half of patients in most randomized controlled trials (RCT) and real-world studies (RWS). Semaglutide and tirzepatide have also displayed a mean 60-69% 10-years relative risk reduction of T2D development. In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly. Moreover, incretin-based therapies have also been proven beneficial on obesity-related comorbidities, such as knee osteoarthritis (KOA), obstructive sleep apnea (OSA) syndrome, and MASLD. Further research is needed to improve our understanding of their effects on obesity-related comorbidities and the underlying mechanism, whether involving direct effects on target tissues or mediated by improvement in BW, glucose levels and other CV risk factors.
Overview
CoChat Summary
TL;DR
This narrative review summarizes incretin-based therapies for obesity and obesity-related diseases, reporting substantial weight loss and benefits for type 2 diabetes prevention, cardiovascular risk factors, and several comorbidities. It concludes that liraglutide, semaglutide, and tirzepatide are effective, with newer agents such as retatrutide, CagriSema, oral semaglutide, and orforglipron in advanced development.
Key findings
- Incretin-based therapies were associated with body weight reduction of ≥5% in at least half of patients in most randomized controlled trials and real-world studies; semaglutide and tirzepatide showed a mean 60–69% 10-year relative risk reduction of type 2 diabetes development.
- In RCTs, liraglutide 3.0 mg produced 6.1–8.0% body weight loss vs. 0.2–4.0% with placebo at 56 weeks; semaglutide 2.4 mg produced 14.8–16.0% vs. 2.4–5.7% at 68 weeks; tirzepatide 15 mg produced 20.9% vs. 3.1% at 72 weeks; retatrutide 12 mg produced up to −24.2% at 48 weeks.
- The SELECT trial showed once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (HR 0.80, 95% CI 0.72–0.90, p < 0.001), heart failure composite endpoint (HR 0.82, 95% CI 0.71–0.96), and death from any cause (HR 0.81, 95% CI 0.71–0.93).
- For comorbidities, SYNERGY-NASH reported biopsy-proven MASH resolution in 62% with tirzepatide 15 mg vs. 10% with placebo; SURMOUNT OSA showed 17.7–19.6% body weight reduction vs. 1.6–2.3% with placebo; SCALE Sleep Apnea showed apnea-hypopnea index reduction of −6.1 events per hour vs. placebo.
Methods
- Design: narrative review of incretin-based therapies for obesity-related diseases, including liraglutide, semaglutide, tirzepatide, retatrutide, CagriSema, oral semaglutide, orforglipron, and other agents in development.
- Data: published randomized controlled trials (SCALE, STEP, SURMOUNT, SELECT, OASIS 1, SYNERGY-NASH, SURMOUNT OSA, etc.), real-world studies, and meta-analyses; no primary patient data were collected.
- Analysis: descriptive synthesis of efficacy, effectiveness, diabetes prevention, cardiovascular risk factors, cardiovascular complications, other obesity-related comorbidities, and treatment adherence, with summary tables and figures.
Limitations
- Stated: further research is needed to understand effects on obesity-related comorbidities and underlying mechanisms, whether direct on target tissues or mediated by improvements in body weight, glucose levels, and other cardiovascular risk factors.
- Stated: adherence, prediction of response to treatment, and economic barriers to access remain unresolved and may require complex, multifaceted approaches.
- Evident: this is a narrative review without a stated systematic search strategy or formal risk-of-bias assessment; many cited trials are ongoing or not yet disclosed (e.g., STEP 10, FLOW, cardiovascular safety trials for tirzepatide and CagriSema), and real-world studies are noted to have small samples, limited adherence/dose information, and approximately 6-month follow-up.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
20 Valid · 3 Not valid · 64 Not checked · 22 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Similarly, patients with type 2 diabetes were also represented in many studies51,53,54,56,57,59,62,63,65,68–71.”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
What the sources say
- Supportedcites [51] Wharton, S. et al. Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. Obesity 27, 917–924 (2019). source
The Results (Table 2, Cohort and baseline characteristics) report that 16 of 311 participants (5.1%) had type 2 diabetes. This confirms that patients with type 2 diabetes were represented in this real-world study; the citation is one of several offered for the broader statement about many studies. (LLM, conf=0.94)
- Not checked yetcites [53] Park, J. H. et al. Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. Int. J. Obes. 45, 776–786 (2021). source
- Supportedcites [54] Liao, Y.-N. et al. Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study. Front. Pharmacol. 13, 978814 (2022). source
The Discussion section states that this real-world study included individuals with type 2 diabetes, particularly in the liraglutide group. That supports citing this paper as one of the studies in which patients with type 2 diabetes were represented. (LLM, conf=0.93)
- Supportedcites [56] Trenson, L. et al. Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. Obes. Facts 15, 83–89 (2022). source
The Patient Characteristics and Treatment Adherence section reports that nine of 115 patients (8%) in this real-world study had type 2 diabetes. This confirms that such patients were represented in the cited study; the other studies in the citation list are not assessed here. (LLM, conf=0.94)
- Not checked yetcites [57] Alshehri, A., AlFaris, N., Al Qahtani, A. M., Shams, M. & Yahia, M. Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience. Clin. Obes. 13, e12594 (2023). source
- Supportedcites [59] Schultes, B., Timper, K., Cavadini, G., Rüh, J. & Gerber, P. A. Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study). Diabetes Obes. Metab. https://doi.org/10.1111/dom.15403 (2023). source
The Inclusion criteria (§2.2; page not available) explicitly allowed participants with type 2 diabetes in both cohorts. The baseline-characteristics section (§3.1; page not available) also lists T2D among the study population’s weight-related comorbidities. This confirms that the ADDRESS study is an example of a real-world study in which patients with type 2 diabetes were represented; it does not establish the claim about how many other studies included them. (LLM, conf=0.87)
- Partly supportedcites [62] Park, J. S., Kwon, J., Choi, H. J. & Lee, C. Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine 100, e23780 (2021). sourceExperimental — accuracy not yet measured
The Results (Baseline characteristics; page not provided) report that 10.1% of patients with HbA1c data had diabetes, so patients with diabetes were represented in this real-world study. The paper does not identify those patients as having type 2 diabetes; it also cannot establish the claim about how many other studies included them. (LLM, conf=0.84)
- Supportedcites [63] Calderon, G. et al. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int. J. Obes. 46, 555–563 (2022). source
The Methods describe a review of patient records from real-world weight-management programs. The Results (Weight-related Comorbidities) report that 32.9% of this study’s patients had type 2 diabetes, confirming that such patients were represented in this cited study. (LLM, conf=0.94)
- Not checked yetcites [65] Alabduljabbar, K., Alsaqaaby, M., Neff, K. J., Crotty, M. & le Roux, C. W. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine https://doi.org/10.1007/s12020-023-03534-0 (2023). source
- Disputedcites [68] Wilmington, R., Ardavani, A., Simenacz, A., Green, C. & Idris, I. Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery. Obes. Surg. https://doi.org/10.1007/s11695-023-06895-7 (2023). sourceExperimental — accuracy not yet measured
The Methods describe the studied patients as having prediabetes or awaiting bariatric surgery and say Saxenda treatment followed guidance for patients with non-diabetic hyperglycaemia. The paper does not identify patients with type 2 diabetes in its cohort; its description of the studied population runs contrary to using it as an example of a study representing those patients. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“At 56 weeks, patients on liraglutide 3.0 mg lost on average 6.1–8.0% of BW vs. 0.2–4.0% on placebo15–17”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Randomized controlled trials (RCT)
What the sources say
- Supportedcites [15] Wadden, T. A. et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity 28, 529–536 (2020). source
The Results (Body weight) report mean weight loss at week 56 of 7.5% with liraglutide 3.0 mg plus intensive behavioral therapy and 4.0% with placebo plus intensive behavioral therapy. Those values fall within the cited ranges; this trial does not itself establish the full ranges attributed to citations 15–17 collectively. (LLM, conf=0.91)
- Not checked yetcites [16] Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int. J. Obes. 37, 1443–1451 (2013). source
- Supportedcites [17] Pi-Sunyer, X. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med. 373, 11–22 (2015). source
The Body Weight section (p. 4) reports mean weight loss at 56 weeks of 8.0% with liraglutide 3.0 mg and 2.6% with placebo. Both values fall within the respective ranges in the sentence, which cites multiple studies. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Results from studies enrolling patients with previous bariatric surgery are in line with those including surgically naïve individuals64,69,72”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
What the sources say
- Not checked yetcites [64] Rye, P., Modi, R., Cawsey, S. & Sharma, A. M. Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery. Obes. Surg. 28, 3553–3558 (2018). source
- Supportedcites [69] Jensen, A. B. et al. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Obes. Surg. 33, 1017–1025 (2023). source
The Conclusion (page not provided) explicitly says that weight loss with GLP-1 receptor agonists in the post-bariatric study was consistent with findings from SCALE, SUSTAIN, and STEP trials involving patients without bariatric surgery. This supports the cited comparison of results in previously operated and surgically naïve patients. (LLM, conf=0.95)
- Partly supportedcites [72] Muratori, F. et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat. Weight Disord. 27, 2775–2781 (2022). sourceExperimental — accuracy not yet measured
The Results report weight loss with liraglutide in patients who had undergone bariatric surgery, and the Discussion compares outcomes across types of surgery. Neither section compares those outcomes with studies of surgically naïve individuals, so the claimed similarity is not established by this paper. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“T2D was reported in up to 1% patients on semaglutide vs. 0.9–3% in those on placebo at 68 weeks73”
§ Incretin-based therapies for the treatment of obesity-related diseases > Incretin-based therapy for diabetes prevention in patients with obesity
What the sources say
- Partly supportedcites [73] Perreault, L. et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care 45, 2396–2405 (2022). sourceExperimental — accuracy not yet measured
The Results section 'Glycemic Status From Week 0 to 68' (and the Abstract RESULTS) report type 2 diabetes at week 68 among participants who had PREDIABETES at week 0: STEP 1 0.5% semaglutide vs. 3.0% placebo; STEP 3 0% vs. 1.0%; STEP 4 0% vs. 0.9%. The placebo range 0.9–3% is therefore supported, but the highest semaglutide figure in our copy is 0.5%, not 'up to 1%', so that bound overstates the source. The claim also drops the population qualifier (adults with overweight/obesity without diabetes at baseline, restricted to those with baseline prediabetes), and our copy presents these as post hoc/exploratory glycemic-status analyses, not reported adverse-event rates for all trial participants. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“treatment with liraglutide 3.0 mg reduced the proportion of patients with prediabetes compared to placebo at 56 weeks regardless of baseline glycemic status (7.2 vs. 20.7% and 30.8 vs. 67.3% in patients with normoglycemia and prediabetes)17”
§ Incretin-based therapies for the treatment of obesity-related diseases > Incretin-based therapy for diabetes prevention in patients with obesity
What the sources say
- Partly supportedcites [17] Pi-Sunyer, X. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med. 373, 11–22 (2015). sourceExperimental — accuracy not yet measured
The Glycemic Control section (p. 4) reports significantly lower prediabetes prevalence with liraglutide than placebo at week 56. The Figure 2 caption (p. 8) reports results separately for patients with normoglycemia and prediabetes at screening, supporting the claim across baseline groups. Our copy does not state the four percentages quoted in the citing sentence, and its 56-week result is from the main trial, not the extension. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
72 more claims · 8 with their cited sources checked
Create a free account to see all 109 claims and to verify the 80 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 2
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These trials also highlighted that weight loss with orforglipron is not solely attributable to gastrointestinal side effects, as progressive reductions were observed after initial dose titration, and appetite suppression was corroborated by patient-reported satiety measures.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
“85.7 to 93.0% with semaglutide”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
“| Ruseva (2024) | −10.5 (6.8) | 79.0 | 48.1 | 19.0 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
“Most studies included a certain proportion of participants with prediabetes (2.5–52.0%).”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
“| Santini (2022) | Switzerland | 54 | 10 | Lira 3.0 mg | 43.6 (11.6) | 64.8 | 40.8 (5.7) | Excluded | 63/0 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Incretin-based therapies for the treatment of obesity-related diseases > Abstract
“triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943)”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Randomized controlled trials (RCT)
“triple biased GLP-1/GIP/GCC receptors agonist retatrutide (LY3437943)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
“females (60–95%)”
§ Incretin-based therapies for the treatment of obesity-related diseases > Efficacy and effectiveness of incretin-based therapies in body weight reduction > Real-world studies
“| Park (2021) | South Korea | 169 | 2.4 | Lira 3.0 mg | 41.5 (9.6) | 58 |”
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“InSTEP 1 and STEP 3, patients on semaglutide lost 14.8 – 16.0% BW compared to 2.4 – 5.7% in the placebo group at 68 weeks 26,27 .”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 3×
“Across the SURMOUNT trials, the proportion of patients losing >5%, 10%, 15% and 20% of body weight was 79.2 – 97.3%, 60.5 – 92.1%, 39.7 – 84.1%, and 21.5 – 69.5%, respectively 34 – 37 ; notably, 9.0 – 54.5% of patients lost >25% of initial body weight 36 (Fig.”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 10×
“A larger study (SEMA-NASH) enrolling 320 individuals with obesity, biopsy-proven NASH and differentdegreesof fi brosis,withorwithoutdiabetes,demonstratedthatOD subcutaneous semaglutide 0.4 mg signi fi cantly resolved MASH without worsening fi brosis in 59% of patients 93 .”
InfluentialSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“A blunted BW reduction wasobservedinpatientswithT2DintheSTEP2trial( − 9.6%vs − 3.4%with semaglutide 2.4 mg and placebo, respectively) 31 and in East-Asian patients with overweight or obesity with/without T2D 32 .”
InfluentialDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Cited by
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Vincenzo, O. D., Minnetti, M., Baker, J. L., Barazzoni, R., Boyland, E. J., Busetto, L., Ciudin, A., Dicker, D., Fábryová, Ľ., Helgason, T., et al. (2025) · Obesity Facts · doi:10.1159/000549751 · Cited by 32
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Masi, D., Watanabe, M., & Clément, K. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102573 · Cited by 25
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Tirzepatide for adults living with obesity
Franco, J. V. A., Guo, Y., Varela, L. B., Aqra, Z., Alhalahla, M., Rodriguez, M. M., Salvador-Oscco, E., Araujo, B. P., Banda, S., Liquitay, C. M. E., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016018 · Cited by 22
Metadata
- Authors
- Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Giorgino, Francesco
- Venue
- npj Metabolic Health and Disease
- Published
- 2024-11-06
- Volume
- 2
- Issue
- 1
- Pages
- 31-31
- ISSN
- 2948-2828 (ISSN-L)
- PMC
- PMC12118674
- OpenAlex
- W4404110396
- Cited by
- 48
- References
- 113
- Citations by year
- 2026: 33 · 2025: 15
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- npj Metabolic Health and Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission (DM 155711.10.2022, 11-10-2022)
- Fondazione per la Ricerca Biomedica
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- incretin-based therapy, obesity, semaglutide, tirzepatide, liraglutide, retatrutide, orforglipron, type 2 diabetes prevention, non-alcoholic fatty liver disease, heart failure, cardiovascular risk, knee osteoarthritis, obstructive sleep apnea, weight loss, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incretin-based therapies for the treatment of obesity-related diseases. https://app.cochat.ai/papers/10.1038/s44324-024-00030-5
- The paper
- Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024). Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. https://doi.org/10.1038/s44324-024-00030-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.